相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib
Ezra Y. Rosen et al.
CLINICAL CANCER RESEARCH (2021)
ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib
Yaogeng Wang et al.
PHARMACOLOGICAL RESEARCH (2021)
OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation
Yaogeng Wang et al.
BRITISH JOURNAL OF PHARMACOLOGY (2020)
Advances in Targeting RET-Dependent Cancers
Vivek Subbiah et al.
CANCER DISCOVERY (2020)
Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry
Rahime Senturk et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
Frequency of Brain Metastases and Multikinase Inhibitor Outcomes in Patients With RET-Rearranged Lung Cancers
Alexander Drilon et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers.
Alexander E. Drilon et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability
Wenlong Li et al.
PHARMACOLOGICAL RESEARCH (2018)
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Shumei Kato et al.
CLINICAL CANCER RESEARCH (2017)
Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry
Oliver Gautschi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation
Stephanie van Hoppe et al.
PHARMACOLOGICAL RESEARCH (2017)
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial
Kiyotaka Yoh et al.
LANCET RESPIRATORY MEDICINE (2017)
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial
Alexander Drilon et al.
LANCET ONCOLOGY (2016)
Role of Organic Anion-Transporting Polypeptides (OATPs) in Cancer Therapy
Nilay Thakkar et al.
AAPS JOURNAL (2015)
Identification of Driving ALK Fusion Genes and Genomic Landscape of Medullary Thyroid Cancer
Jun Ho Ji et al.
PLOS GENETICS (2015)
What do drug transporters really do?
Sanjay K. Nigam
NATURE REVIEWS DRUG DISCOVERY (2015)
Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar
Seng Chuan Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption
Yoshihisa Shitara et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2013)
Cabozantinib in Progressive Medullary Thyroid Cancer
Rossella Elisei et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Structure and Physiology of the RET Receptor Tyrosine Kinase
Carlos F. Ibanez
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2013)
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamilies
Megan Roth et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Samuel A. Wells et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clarithromycin Is Absorbed by an Intestinal Uptake Mechanism That Is Sensitive to Major Inhibition by Rifampicin: Results of a Short-Term Drug Interaction Study in Foals
Jette Peters et al.
DRUG METABOLISM AND DISPOSITION (2012)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel
Yong Zhang et al.
COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE (2010)
Membrane transporters in drug development
Kathleen M. Giacomini et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Impact of OATP transporters on pharmacokinetics
A. Kalliokoski et al.
BRITISH JOURNAL OF PHARMACOLOGY (2009)
Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family
B. Hagenbuch et al.
XENOBIOTICA (2008)
Tissue distribution and ontogeny of mouse organic anion transporting polypeptides (Oatps)
XG Cheng et al.
DRUG METABOLISM AND DISPOSITION (2005)
Organic anion transporting polypeptides of the OATP/SLC21 family:: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties
B Hagenbuch et al.
PFLUGERS ARCHIV-EUROPEAN JOURNAL OF PHYSIOLOGY (2004)
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview
AH Schinkel et al.
ADVANCED DRUG DELIVERY REVIEWS (2003)
The superfamily of organic anion transporting polypeptides
B Hagenbuch et al.
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES (2003)
分享论文
